| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.13 | 8e-05 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0002 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |